Atezolizumab, a humanized monoclonal antibody targeting PD-L1, is an immune checkpoint inhibitor approved as a first-line treatment for metastatic non-small cell lung cancer (mNSCLC) exhibiting high PD-L1 expression [1, 2]. Here, CD274 is linked to non-small cell lung carcinoma.